GLP-1 ANALOG USEFUL FOR TREATING DIABETES

PROBLEM TO BE SOLVED: To solve problems that a conventional GLP-1 peptide analog has a short circulation half-life and it is not clear by what effects on characteristics an improvement in effectiveness is obtained. SOLUTION: Effective analogs of active GLP-1 peptides 7-34, 7-35, 7-36 and 7-37 having...

Full description

Saved in:
Bibliographic Details
Main Authors MALLORY JOANNE B, MOJSOV SVETLANA, HABENER JOEL F, BUCKLEY DOUGLAS I
Format Patent
LanguageEnglish
Published 05.06.2001
Edition7
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:PROBLEM TO BE SOLVED: To solve problems that a conventional GLP-1 peptide analog has a short circulation half-life and it is not clear by what effects on characteristics an improvement in effectiveness is obtained. SOLUTION: Effective analogs of active GLP-1 peptides 7-34, 7-35, 7-36 and 7-37 having an improved characteristic for treatment of type II diabetes are obtained to solve the problems. The analogs contain an amino acid substituted at the 7-10 positions and the cleaved C-terminal and/or various other amino acid substitutions in the basic peptide and is improved in ability to stimulate the insulin production as compared with glucagon and capable of improving the stability in plasmas as compared with the GLP-1 (7-37) or both. The ability of the analogs as a therapeutic agent is improved by the characteristic. Analogs having a D-form amino acid substitution at the 7- and the 8-positions and/or an N-alkylated or an N-acylated amino acid at the 7-position are especially resistant to degradation in vivo.
Bibliography:Application Number: JP20000311202